NCT05638620CompletedPhase 1
Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID
Evaluating the Effectiveness of Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Post-Acute Sequelae of SARS-CoV-2 (PASC)
Source: ClinicalTrials.gov · Last updated 13 Mar 2025
Brief summary (registry, in English)
The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 22 Nov 2022
- Start date
- 3 Jan 2023
- Primary completion date
- 15 Jun 2023
- Lead sponsor
- Jonathann Kuo, MD
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT05638620
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 20
- From 3 Jan 2023 to the primary completion date, 15 Jun 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior SGB
Other illness
- Allergy to amide local anesthetics (e.g., ropivacaine, bupivacaine/Marcaine)
- History of a bleeding disorder
- History of glaucoma
- Infection or mass at injection site
Age
- Under age 18
Other
- Pregnancy
- Current anticoagulant use
- For the consistency of this study, patients who deny all autonomic symptoms on the COMPASS-31 or pain symptoms on the PROMIS-29 will also be excluded
Who the study is looking for
- Prior confirmed COVID-19 diagnosis by standard RT-PCR assay or equivalent testing
- Persistent symptoms that continue four or more weeks after the start of a COVID-19 infection
- Quantified autonomic symptoms from at least one domain as reported by the patient on the screener Composite Autonomic Symptom Score (COMPASS-31). The COMPASS-31 assesses 6 domains of autonomic symptoms: Orthostatic Intolerance, Vasomotor, Secretomotor, Gastrointestinal, Bladder, and Pupillomotor.
- Quantified pain symptoms of pain interference or pain intensity as reported by the patient on the screener Patient-Reported Outcomes Measurement Information System (PROMIS-29)
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hudson Medical Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.